NeuPath and Cynergi will bring VR therapy to chronic pain management

NeuPath has signed a Memorandum of Understanding (MoU) with Cynergi to evaluate the effectiveness of the company’s virtual reality (VR) program for chronic pain management.

“Chronic pain is the leading cause of disability worldwide. Studies estimate that the cost of this loss of productivity exceeds $ 300 billion a year in the United States alone, ”said Harbir Singh, CEO of Cynergi.

Singh added: “Collaborating with NeuPath and creating a holistic chronic pain treatment program provides an exceptional opportunity to work with employers and other contributors to improve patients’ quality of life, while reducing disability – related costs and other direct health costs “.

Under the new agreement, Cynergi’s Rilaxta VRx will be used alongside NeuPath’s virtual pain control and virtual care platform across Canada and the United States.

Adding VR software to traditional interventions can provide great benefits in behavioral pain management.

Cynergi’s proprietary virtual reality tools combine calming images and sound with proven psychological techniques to reduce anxiety and panic. Developed by renowned Harvard psychiatrist Arshya Vahabzadeh, Cynergi’s VR program also includes guided therapy for benzodiazepine, alcohol, and opioid addiction.

NeuPath Pain Treatment Centers provide multimodal treatments for patients with chronic pain. Together, Cynergi and NeuPath aim to offer customized RV treatment plans for psychological and behavioral pain.

Earlier this month, NeuPath acquired the virtual care platform KumoCare. Designed to reduce waiting times, KumoCare allows secure video chat with doctors.

Outstanding resources

Trusted technology

How to protect your most valuable product

Download now

Take up the challenge

Shaping the workplace of the future

Download now

The future of CIAM

Four trends that shape access and identity management

Download now

Five questions to ask before upgrading to a modern SIEM

Need a better defense strategy?

Download now

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *